GILD
GILD clinical trials: GILEAD SCIENCES, INC.
Every trial on ClinicalTrials.gov where GILEAD SCIENCES, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 1,271
- Trials linked
- 736
- As lead sponsor
- 535
- As collaborator
- 5
- Primary completions as lead sponsor, next 90 days
GILD on the catalyst calendar · GILD registry changes
- Primary completion Dec 2031Sponsor estimatePhase 1NCT07304154Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual TreatmentKite, A Gilead Company · Chronic Inflammatory Demyelinating PolyneuropathyRecruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 3, 2026ActualPhase 2/Phase 3NCT06544733Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1...Gilead Sciences · HIV-1-InfectionTerminatedGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2039Sponsor estimatePhase 3NCT07903506To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaKite, A Gilead Company · Newly Diagnosed Multiple MyelomaNot yet recruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2028Sponsor estimatePhase 1NCT06167317Study of GS-0201 Alone and in Combination in Participants With Advanced Solid TumorsGilead Sciences · Advanced Solid TumorsRecruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 27, 2026ActualPhase 2NCT02932150Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus InfectionGilead Sciences · Chronic Hepatitis BActive, not recruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2029Sponsor estimatePhase 1NCT07601243Study of GS-2426 in Participants With Advanced Solid TumorsGilead Sciences · Advanced Solid TumorsRecruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2030Sponsor estimatePhase 2/Phase 3NCT07708727Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentGilead Sciences · HIV-1-infectionRecruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 2NCT07645287A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1Gilead Sciences · HIV-1-infectionRecruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2030Sponsor estimatePhase 2NCT07546812Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction...Gilead Sciences · HER2-negativeActive, not recruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 4NCT06337032A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV...Gilead Sciences · HIV-1-infectionRecruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 29, 2025ActualPhase 2/Phase 3NCT05502341Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated...Gilead Sciences · HIV-1-infectionActive, not recruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 3NCT05633654Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast...Gilead Sciences · Triple Negative Breast CancerRecruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2029Sponsor estimatePhase 1NCT07703878A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid TumorsGilead Sciences · Solid TumorRecruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 1/Phase 2NCT06303505FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLCGilead Sciences · Ovarian CancerRecruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2030Sponsor estimatePhase 3NCT06051617Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisGilead Sciences · Primary Biliary CholangitisRecruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT05776134Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelKite, A Gilead Company · Mantle Cell LymphomaAvailableGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2027Sponsor estimatePhase 2NCT07912996Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Genital HerpesGilead Sciences · HSV-2 InfectionNot yet recruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2028Sponsor estimatePhase 4NCT07908446Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIVGilead Sciences · HIV-1 InfectionNot yet recruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2030Sponsor estimatePhase 1/Phase 2NCT04989803Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell LymphomaKite, A Gilead Company · Relapsed and/or Refractory B-cell LymphomaActive, not recruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 2NCT07841977Study of Seladelpar and Cilofexor in Participants With Primary Biliary CholangitisGilead Sciences · Primary Biliary CholangitisRecruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2031Sponsor estimatePhase 3NCT07479797Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell...Kite, A Gilead Company · Relapsed or Refractory Large B-cell LymphomaActive, not recruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 2NCT07841990Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus LevelsGilead Sciences · HIV-1 InfectionRecruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2028Sponsor estimatePhase 1NCT07128303Study of GS-5319 Given Alone or in Combination in Adults With Solid TumorsGilead Sciences · Advanced Solid TumorRecruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2029Sponsor estimatePhase 3NCT06486441Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based...Gilead Sciences · Endometrial CancerActive, not recruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 2NCT07527858Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerGilead Sciences · Advanced Microsatellite Stable Colorectal CancerRecruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 1,246 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner